MedTrace Logo

Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin

NCT01127906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2010-09-23

No results posted yet for this study

Summary

PF-04531083 has been shown to reduce the amount of heat pain experienced by rats with skin that has been sensitized to heat by ultraviolet light. This study is designed to see if this is also true in man.

Conditions

  • Healthy

Interventions

DRUG

PF-04531083 100mg

Oral PF-04531083 100mg suspension single dose

DRUG

PF-04531083 2000mg

Oral PF-04531083 2000mg suspension single dose

DRUG

Placebo suspension

Oral Placebo suspension (matched to PF-04531083 suspension)

DRUG

Placebo tablet

Oral Placebo tablet (matched to Oxycodone)

DRUG

Oxycodone 20mg

Oral Oxycodone 20mg (Oxycontin) controlled release formulation

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01127906 on ClinicalTrials.gov